机构地区: 暨南大学管理学院会计学系
出 处: 《科技管理研究》 2015年第21期35-40,共6页
摘 要: 基于高层梯队理论和相似-吸引范式,将职位层级视为高管团队特征的一个重要因素,探讨高管团队中垂直对人口特征差异与生物医药上市公司R&D投资倾向的关系。研究发现:总经理-高管年龄异质性、教育水平异质性均与R&D投资强度负相关;总经理-高管任期异质性、职业背景异质性与R&D投资强度正相关。此外,管理费用率、资产负债率、总经理兼任董事长与R&D投资强度正相关,公司规模与R&D投资强度负相关。最后对生物医药企业合理配置高管团队以及促进和优化R&D投资等方面提出实践建议。 Based on the upper echelons theory and similarity - attraction paradigm, this paper regards top management team (TMT) characteristics as an important factor and discusses the relationship between TMT vertical dyads heterogeneity and R&D investment of the bio - pharmaceutical listed companies using the demographics differences between CEO and TMT to measure TMT vertical dyads heterogeneity. The conclusions are : CEO - TMT age heterogeneity and CEO - TMT ed- ucation level heterogeneity are negatively related to R&D investment intensity, while the CEO -TMT tenure heterogeneity and CEO - TMT career background heterogeneity are positively related. This paper also finds that the management expense ratio, asset- liability ratio and CEO concurrently be chairman are positively related to R&D investment intensity, while firm size is negatively related in the bio - pharmaceutical industry. Finally, we give some suggestion for improving R&D investment through rationally arranging the top management team (TMT) .
领 域: [经济管理]